ClinicalTrials.gg
RecruitingNCT06315400Updated Apr 1, 2024

Efficacy and Safety of Ingavirin®, Capsules, 60 mg, in Children With Influenza and Other Acute Respiratory Viral Infections

A Phase 4 interventional study of Ingavirin® and Placebo in Influenza, Human, Acute Respiratory Infection and Common Cold, sponsored by Valenta Pharm JSC. Recruiting at 3 sites in Russian Federation. Open to participants aged 13 Years to 17 Years. Per ClinicalTrials.gov, last updated 2024-04-01.

Sponsored by Valenta Pharm JSC · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Dec 2023; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
13 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Influenza, Human by Valenta Pharm JSC — 4 open to participants now, 4 under way, none of them phase 3. Influenza, Human · Valenta Pharm JSC.

Planned enrollment
12th of 15
80 · median 240
Started
2023
the only one that year
Phase 4
2 of 15
1 open now
Registered
12th of 15
by date

Among the 15 studies in Influenza, Human by Valenta Pharm JSC, this one is the 12th largest by planned enrollment, is the only one that started in 2023, is one of 2 in phase 4, and was the 12th registered.

Influenza, Human

2,358 studies on the registry are indexed under Influenza, Human; 184 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

4 of the 15 studies in Influenza, Human by Valenta Pharm JSC are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 121 Influenza, Human studies recruiting now, 66 (55%) set no upper age limit and 45 (37%) stop at 75 or younger; 33 take children under 18; 67 take healthy volunteers.

This study: 13 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Influenza, Human by Valenta Pharm JSC, or all of them as a file.
02

Study summary

The study is planned to evaluate the therapeutic efficacy and safety of Ingavirin®, capsules, 60 mg, in the treatment of influenza or other acute respiratory infections in children from 13 to 17 years compared with placebo.

03

Conditions studied

  • Influenza, Human
  • Acute Respiratory Infection
  • Common Cold
04

Who can participate

Ages eligible
13 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female patients aged 13 to 17 years inclusive.
  2. Clinically established diagnosis of influenza or acute respiratory viral infection based on the presence of body temperature > 37.5 °C and at least 1 of the following symptoms of intoxication syndrome, and at least 1 manifestation of catarrhal syndrome: symptoms of intoxication syndrome (headache, chills, weakness, brokenness, eyeball pain, nausea); catarrhal syndrome (sore throat, rhinitis, pharyngitis, laryngitis, cough).
  3. Laboratory-confirmed diagnosis of influenza or acute respiratory viral infections using one or more of the following viral antigen detection methods.
  4. Uncomplicated course of influenza or ARVI.
  5. Interval between the onset of the first symptoms of the disease and inclusion in the study no more than 36 h.
  6. Availability of an form signed by one of the parents (or legal representatives) of the child for participation in the study.
  7. For patients 14 years and older, a signed informed consent form for participation in the study.

Exclusion criteria

Exclusion Criteria:

  1. to any of the components included in the Ingavirin®.
  2. Complicated course of influenza and acute respiratory viral infections (clinically and laboratory determined bacterial infection).
  3. Taking antiviral drugs (antiviral agents, interferons, interferon inducers and drugs with immunomodulatory effect) or systemic antibacterial agents 7 days prior to the Screening Visit.
  4. Severe influenza with signs of cardiovascular failure and other manifestations of infectious-toxic shock, as well as with the presence of neuroinfection syndrome (encephalic and meningoencephalic reactions).
  5. Signs of viral pneumonia (presence of two or more of the following symptoms: dyspnea, chest pain when coughing, systemic cyanosis, dulling of the percussion sound with symmetric evaluation of the upper and lower lungs).
  6. Infectious diseases suffered during the last week before inclusion of the patient in the study.
  7. "Frequently ill children" (frequency of acute respiratory illnesses during the last year 6 times or more).
  8. A history of bronchial asthma.
  9. A history of increased seizure activity.
  10. Severe, decompensated or unstable somatic diseases (any diseases or conditions that threaten the patient's life or worsen the patient's prognosis, as well as make it impossible to conduct a clinical trial in the patient).
  11. History of oncologic diseases, infection, tuberculosis.
  12. Diabetes mellitus, lactose intolerance, lactase deficiency, glucose-galactose malabsorption, sucrose/isomaltase deficiency, fructose intolerance, hereditary disorders of glucose absorption, glucose-6-phosphate dehydrogenase deficiency.
  13. Participation in a clinical drug trial less than 3 months prior to the start of the study.
  14. Immunization of the patient 14 days prior to the Screening Visit.
  15. The need for concomitant therapy with any of the drugs listed under "Prohibited Concomitant Treatment".
  16. Any other concomitant somatic diseases or conditions that, in the opinion of the investigator, make it difficult to interpret the results of treatment or result in the inability to perform the procedures in this clinical trial or pose a risk to the patient in participating in the study.
  17. For female patients, a positive urine pregnancy test if menstrual cycle is present.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Ingavirin®, capsules, 60 mg

    Ingavirin® will be administered once a day (60 mg/day) for 5 days on top of standard therapy.

    Drug: Ingavirin®

  • Placebo comparator
    Placebo

    Placebo will be administered once a day for 5 days on top of standard therapy.

    Drug: Placebo

Interventions

  • 60 mg/day for 5 days

  • DrugPlacebo

    1 capsule/day for 5 days

06

What researchers measure

Primary outcomes

  1. Percentage of patients with normalization of body temperature at Visit 3 (Day 3)

    Percentage of patients with body temperature \<37ºС with no rise above these values in the subsequent period until Visit 7

    Time frame: Day 0 - Day 21±1

Secondary outcomes

  1. Timeframe for normalization of body temperature from the start of treatment, measured in hours

    Time (hours) to reach body temperature \<37ºС with no rise above these values in the subsequent period until Visit 7 (Day 21±1)

    Time frame: Day 0 - Day 21±1

  2. Time of cough disappearance from the moment of treatment initiation

    Disappearance of cough; no recurrence of cough in the following days of observation

    Time frame: Day 0 - Day 21±1

  3. Percentage of patients with absence of catarrhal syndrome

    Percentage of patients with disappearance of all manifestations; no recurrence on subsequent days of follow-up) at Visit 3 (Day 3)

    Time frame: Day 0 - Day 21±1

  4. Percentage of patients with absence of intoxication syndrome

    Percentage of patients with disappearance of all manifestations; no recurrence on subsequent days of follow-up) at Visit 3 (Day 3)

    Time frame: Day 0 - Day 21±1

  5. Average body temperature on days 1, 2, 3, 4 and 5 from the start of therapy

    Average body temperature (two measurements per a day)

    Time frame: Day 1 - Day 5

  6. Percentage of patients with complications of influenza/acute respiratory infection that developed between days 1-6 and days 1-21 from the start of study drug administration

    Percentage of patients with at least one complication of disease

    Time frame: Day 0 - Day 21±1

  7. Percentage of patients with severe complications of influenza/acute respiratory infection that developed between days 1-6 and days 1-21 from the start of study drug administration

    Percentage of patients with at least one severe complication of disease

    Time frame: Day 0 - Day 21±1

  8. Assessment of vital signs: blood pressure

    Blood pressure, mmHg

    Time frame: Day 1, Day 3, Day 6

  9. Assessment of vital signs: heart rate

    Heart rate, bpm

    Time frame: Day 1, Day 3, Day 6

  10. Assessment of vital signs: respiratory rate

    Respiratory rate, bpm

    Time frame: Day 1, Day 3, Day 6

  11. Assessment of vital signs: body temperature

    Temperature, ºС

    Time frame: Day 1 - Day 6

  12. Evaluation of concomitant therapy

    Number and types of concomitant therapy

    Time frame: Day 0 - Day 21±1

  13. Laboratory evaluation: leukocyte formula

    Precentage of white blood cells of different types

    Time frame: Day 1, Day 6

  14. Laboratory evaluation: hemoglobin

    Hemoglobin, g/L

    Time frame: Day 1, Day 6

  15. Laboratory evaluation: leukocyte count

    Cell/mL

    Time frame: Day 1, Day 6

  16. Laboratory evaluation: platelet count

    Cell/mL

    Time frame: Day 1, Day 6

  17. Laboratory evaluation: red blood cell count

    Cell/mL

    Time frame: Day 1, Day 6

  18. Laboratory evaluation: hematocrit

    Hematocrit, %

    Time frame: Day 1, Day 6

  19. Laboratory evaluation: erythrocyte sedimentation rate

    mm/h

    Time frame: Day 1, Day 6

  20. Laboratory evaluation: blood glucose

    mmol/L

    Time frame: Day 1, Day 6

  21. Laboratory evaluation: total protein

    g/L

    Time frame: Day 1, Day 6

  22. Laboratory evaluation: total bilirubin

    mcmol/L

    Time frame: Day 1, Day 6

  23. Laboratory evaluation: AST

    U/L

    Time frame: Day 1, Day 6

  24. Laboratory evaluation: ALT

    U/L

    Time frame: Day 1, Day 6

  25. Laboratory evaluation: creatinine

    mcmol/L

    Time frame: Day 1, Day 6

  26. Laboratory evaluation: urea

    mmol/L

    Time frame: Day 1, Day 6

  27. Laboratory evaluation: triglycerides

    mmol/L

    Time frame: Day 1, Day 6

  28. Laboratory evaluation: urinalysis

    Urune color, transparency, specific gravity, pH, presence of protein, glucose, bilirubin, microscopy of urine sediment (epithelium, erythrocytes, leukocytes, cylinders, bacteria, salts)

    Time frame: Day 1, Day 6

  29. Frequency of adverse events (AEs) and serious adverse events (SAEs)

    Total number and frequency of AEs and SAEs stratified by severity and frequency

    Time frame: Day 0 - Day 21±1

  30. Percentage of patients who discontinued study due to AE/SAE

    Percentage of patients who discontinued study participation early due to the occurrence of AE/SAE and time to dropout due to AE/SAE

    Time frame: Day 0 - Day 21±1

07

Study locations

3 of 3 sites recruiting
  • GBOU VPO "Rostov State Medical University" of Ministry of Health of Russian Federation
    Rostov-na-Donu, Russian Federation
    Recruiting
  • GBOU VPO "Siberia State Medcial University" of Ministry of Health of Russian Federation
    Tomsk, Russian Federation
    Recruiting
  • GBOU VPO "Yaroslavl State Medical University" of Ministry of Health of Russian Federation
    Yaroslavl, 150000, Russian Federation
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Dec 2025, 24 months after the start.

Of 37 industry-sponsored phase 4 interventional studies under Influenza, Human, half reached primary completion within 3 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 6. This study's planned 24 months is above that.

Counting every sponsor, half of 138 studies reached it within 14 months; a quarter within 3 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2024
First posted
Mar 18, 2024
StartActual
Dec 19, 2023
Primary completionEst.
Dec 31, 2025
CompletionEst.
Dec 31, 2025
Last update
Apr 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06315400
Lead sponsor
Valenta Pharm JSC
Responsible party
Sponsor
First posted
Mar 18, 2024
Start date
Dec 19, 2023
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Apr 1, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pentanedioic acid imidazolyl ethanamide

Start the discussion